BCAB — BioAtla, Inc.
—
OTC ·
Health Care ·
Biotechnology ·
CIK 1826892 ·
Last close
$1.80
Market Cap
$3.00M
52W High
$71.50
52W Low
$1.07
ADV30
6,227
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 250,000 | — | -3,497,000 | -7,897,000 | 1,109,000 | 576,000 | 44,705,000 |
| Jun 2026 | 6,500,000 | — | 227,000 | 452,000 | 9,506,000 | 1,544,000 | 45,742,000 |
| Mar 2026 | 0 | — | -9,308,000 | -6,344,000 | 8,566,000 | 1,961,000 | 45,875,000 |
| Dec 2025 | 2,000,000 | — | -9,255,000 | -9,784,000 | 13,828,000 | 7,118,000 | 50,017,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,482,000
Investing CF
$0
Financing CF
$6,819,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-25.45
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-551,538,000
Inventory
—
Receivables
$2,000,000
ST Investments
—
EBIT TTM
$-32,125,000
Pretax Income TTM
$-31,454,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$8,500,000
EBITDA
$-30,830,000
Free Cash Flow
$-11,860,625
Enterprise Value
$6,818,150
Total Cash
$1,544,000
Total Debt
$5,863,000
Shares Out
1,666,100
Trailing EPS
$-25.07
Book Value
$-21.79
ROE
—
ROA
-105.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,000,000 | -59,305,000 | -59,607,000 | 13,828,000 | 50,017,000 | -36,189,000 | -48,204,000 |
| Dec 2024 | 11,000,000 | -73,943,000 | -69,776,000 | 52,422,000 | 38,157,000 | 14,265,000 | -71,936,000 |
| Dec 2023 | 0 | -129,687,000 | -123,462,000 | 119,658,000 | 48,986,000 | 70,672,000 | -104,015,000 |
| Dec 2022 | 0 | -108,140,000 | -106,482,000 | 225,736,000 | 45,397,000 | 180,339,000 | -90,420,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$263,000
NetIncome TTM
$-31,454,000
OpCashFlow TTM
—
Assets (Latest)
$9,506,000
Forward EPS
$-1.34
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SNTI | Senti Biosciences Holdings, Inc. | $3.02M | $0.10 | — |
| ABPO | Abpro Holdings, Inc. | $2.65M | $0.45 | — |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | $3.62M | $0.48 | — |
| CRIS | CURIS INC | $3.62M | $0.54 | — |
| VIVS | VivoSim Labs, INC. | $2.44M | $0.12 | — |
News headlines (Yahoo Finance, 1h cache)
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
2026-03-31 20:05 · Yahoo
BioAtla Announces Share Consolidation
2026-03-31 20:06 · Yahoo
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
2026-05-18 10:45 · Yahoo
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
2026-03-02 12:30 · Yahoo
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma
2025-12-31 12:00 · Yahoo
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
2025-11-21 05:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.